Results 191 to 200 of about 1,320,527 (284)

Safety and efficacy of early initiation of mineralocorticoid receptor antagonist after an acute decompensated heart failure event or acute myocardial infarction with cardiac dysfunction: a meta-analysis of randomized clinical trials. [PDF]

ESC Heart Fail
Laborante R, Paglianiti DA, Elia S, Patti G, Girerd N, Savarese G, D'Amario D.   +6 more
europepmc   +1 more source

Effectiveness of Telehealth Low‐Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real‐World, Retrospective, Matched Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9054-9068, October 2026.
ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan, Petter Bjornstad, Priya V. Shanmugam, Thomas Weimbs, Adam J. Wolfberg, Jeff S. Volek, Jonathan Himmelfarb, Richard J. Johnson   +7 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonist Pre-Adrenalectomy in Primary Aldosteronism.

J Clin Endocrinol Metab
Goi J, Paja Fano M, Rizo Gellida A, González-Boillos M, Martín Rojas-Marcos P, Caja Guayerbas L, García Cano AM, Ruiz-Sanchez JG, Vicente A, Gómez-Hoyos E, Recasens M, Barahona San Millan R, Picón César MJ, Díaz Guardiola P, Perdomo CM, Manjón-Miguélez L, Rebollo Román Á, Robles Lázaro C, Recio-Cordova JM, Calatayud M, Jiménez López N, Sampedro Nuñez M, Mena Ribas E, Sanmartín Sánchez A, Gonzalvo Diaz C, Lamas C, Serrano J, Michalopoulou T, Tenes Rodrigo S, Pascual-Corrales E, Jaén Aguila F, Muñoz Rivas N, Moya Mateo EM, Gutiérrez-Medina S, Hanzu FA, Parra Ramírez P, Araujo-Castro M.   +36 more
europepmc   +1 more source

Association Between Mineralocorticoid Receptor Antagonist Use With Worsening Renal Function and Prognosis in Patients With Acute Heart Failure. [PDF]

J Am Heart Assoc
Fujimoto Y, Shiraishi Y, Nogi K, Kohsaka S, Kohno T, Kitamura M, Nagatomo Y, Ueda T, Nogi M, Ishihara S, Nakada Y, Kawakami R, Kitai T, Oishi S, Akiyama E, Suzuki S, Yamamoto M, Kida K, Okumura T, Yoshikawa T, Saito Y, Matsue Y.   +21 more
europepmc   +1 more source

Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9412-9422, October 2026.
ABSTRACT Aims To assess the feasibility of a decentralised response‐guided trial and to characterise urinary albumin‐to‐creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2,
Jelle M. Beernink, Gozewijn D. Laverman, Hiddo J. L. Heerspink   +2 more
wiley   +1 more source

Observation of the therapeutic effect of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, in patients with non-diabetic CKD. [PDF]

Ren Fail
Li F, Han J, Zhang W, Lv J, Wang Z, Li H, Jin L, Feng J, Lu W, Sun J.   +9 more
europepmc   +1 more source

Absence of Interaction Between 5α‐Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9543-9551, October 2026.
ABSTRACT Aims People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α‐reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co‐prescription of both drugs.
Haolan Tu, Chengsheng Ju, Stuart J. McGurnaghan, Luke A. K. Blackbourn, Scottish Diabetes Research Network Epidemiology Group, Peter Hanlon, Robert Lindsay, David McAllister, John Petrie, Naveed Sattar, Brian Kennon, Sam Philip, Scott Cunningham, Huan Wang, William Berthon, Helen Colhoun, Paul McKeigue, Sarah Wild, Ewan R. Pearson, Li Wei, Ruth Andrew   +20 more
wiley   +1 more source

Implication of the Dose of Mineralocorticoid Receptor Antagonist Following Transcatheter Edge-to-Edge Mitral Valve Repair. [PDF]

JACC Asia
Imamura T, Tanaka S, Fukuda N, Ueno H, Kinugawa K, Kubo S, Yamamoto M, Izumi Y, Saji M, Asami M, Enta Y, Shirai S, Izumo M, Mizuno S, Watanabe Y, Amaki M, Kodama K, Yamaguchi J, Naganuma T, Bota H, Ohno Y, Hachinohe D, Yamawaki M, Mizutani K, Otsuka T, Hayashida K, the, OCEAN-Mitral Investigators.   +27 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study (MEDFINE‐RWD)

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9461-9472, October 2026.
ABSTRACT Aim Although finerenone has shown efficacy in randomized trials, evidence from routine clinical practice remains limited. We aimed to assess the real‐world effectiveness and safety of finerenone in people with type 2 diabetes (PWT2D) and chronic kidney disease (CKD), with a particular focus on residual cardiorenal risk as reflected by changes ...
Oscar Moreno‐Pérez, Antonio Tejera‐Muñoz, Patricia Tomás‐Gómez, Federico Vázquez‐San Miguel, Virginia Soria‐Utrilla, Ada María Roldán‐Sánchez, Maya Sánchez‐Baya, Jersy Cárdenas‐Salas, Blanca Timón‐Vázquez, Juan J. Gorgojo‐Martínez, Ines Modrego‐Pardo, Irea Fernández‐Xove, Jose Carlos Fernández‐García, Rebeca Reyes‐García   +13 more
wiley   +1 more source

Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS). [PDF]

Pragmat Obs Res
Richard EL, Stephenson JJ, Desai NR, Willey VJ, Gay A, Scott C, Folkerts K, Pessina E, Singh R, Teng CC, Oberprieler NG.   +10 more
europepmc   +1 more source